Domenico Maione

Domenico Maione

Auto-generated profile, based on publicly available information

Domenico Maione

GSK, Siena, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Vaccine
Verified
Journal Article
Open access
GMGiulietta Maruggi
Giulietta Maruggi
ECEmiliano Chiarot
Emiliano Chiarot
CGCinzia Giovani
Cinzia Giovani
SBScilla Buccato
Scilla Buccato
SBStefano Bonacci
Stefano Bonacci
DMDomenico Maione
Domenico Maione
Nucleic acid vaccines represent an attractive approach to vaccination, combining the positive attributes of both viral vectors and live-attenuated vaccines, without the inherent limitations of each technology. We have developed a novel technology, the Self-Amplifying mRNA (SAM) platform, which is based on the synthesis of self-amplifying mRNA formulated and delivered as a vaccine. SAM vaccines have been shown to stimulate robust innate and adaptive immune responses in small animals and non-human primates against a variety of viral antigens, thus representing a safe and versatile tool against viral infections. To assess whether the SAM technology could be used for a broader range of targets, we investigated the immunogenicity and efficacy of SAM vaccines expressing antigens from Group A (GAS) and Group B (GBS) Streptococci, as models of bacterial pathogens. Two prototype bacterial antigens (the double-mutated GAS Streptolysin-O (SLOdm) and the GBS pilus 2a backbone protein (BP-2a)) were successfully expressed by SAM vectors. Mice immunized with both vaccines produced significant amounts of fully functional serum antibodies. The antibody responses generated by SAM vaccines were capable of conferring consistent protection in murine models of GAS and GBS infections. Inclusion of a eukaryotic secretion signal or boosting with the recombinant protein resulted in higher specific-antibody levels and protection. Our results support the concept of using SAM vaccines as potential solution for a wide range of both viral and bacterial pathogens, due to the versatility of the manufacturing processes and the broad spectrum of elicited protective immune response.

13 February 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
BCBjörn Corleis
Björn Corleis
DHDonata Hoffmann
Donata Hoffmann
SRSusanne Rauch
Susanne Rauch
CFCharlie Fricke
Charlie Fricke
NRNicole Roth
Nicole Roth
ADAnca Dorhoi
Anca Dorhoi
Combining optimized spike (S) protein-encoding mRNA vaccines to target multiple SARS-CoV-2 variants could improve control of the COVID-19 pandemic. We compare monovalent and bivalent mRNA vaccines encoding B.1.351 (Beta) and/or B.1.617.2 (Delta) SARS-CoV-2 S-protein in a transgenic mouse and a Wistar rat model. The blended low-dose bivalent mRNA vaccine contains half the mRNA of each respective monovalent vaccine, but induces comparable neutralizing antibody titres, enrichment of lung-resident memory CD8+ T cells, antigen-specific CD4+ and CD8+ responses, and protects transgenic female mice from SARS-CoV-2 lethality. The bivalent mRNA vaccine significantly reduces viral replication in both Beta- and Delta-challenged mice. Sera from bivalent mRNA vaccine immunized female Wistar rats also contain neutralizing antibodies against the B.1.1.529 (Omicron BA.1 and BA.5) variants. These data suggest that low-dose and fit-for-purpose multivalent mRNA vaccines encoding distinct S-proteins are feasible approaches for extending the coverage of vaccines for emerging and co-circulating SARS-CoV-2 variants.

6 October 2023 in npj Vaccines
Verified
Journal Article
Open access
PDF file
FCFilippo Carboni
Filippo Carboni
RCRoberta Cozzi
Roberta Cozzi
GRGiacomo Romagnoli
Giacomo Romagnoli
GTGiovanna Tuscano
Giovanna Tuscano
CBCristiana Balocchi
Cristiana Balocchi
MRMaria Rosaria Romano
Maria Rosaria Romano
A maternal vaccine to protect neonates against Group B Streptococcus invasive infection is an unmet medical need. Such a vaccine should ideally be offered during the third trimester of pregnancy and induce strong immune responses after a single dose to maximize the time for placental transfer of protective antibodies. A key target antigen is the capsular polysaccharide, an anti-phagocytic virulence factor that elicits protective antibodies when conjugated to carrier proteins. The most prevalent polysaccharide serotypes conjugated to tetanus or diphtheria toxoids have been tested in humans as monovalent and multivalent formulations, showing excellent safety profiles and immunogenicity. However, responses were suboptimal in unprimed individuals after a single shot, the ideal schedule for vaccination during the third trimester of pregnancy. In the present study, we obtained and optimized self-assembling virus-like particles conjugated to Group B Streptococcus capsular polysaccharides. The resulting glyco-nanoparticles elicited strong immune responses in mice already after one immunization, providing pre-clinical proof of concept for a single-dose vaccine.

2 October 2020 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
DVDaniele Veggi
Daniele Veggi
FBFederica Bianchi
Federica Bianchi
LSLaura Santini
Laura Santini
PSPaola Lo Surdo
Paola Lo Surdo
CCChelsy C. Chesterman
Chelsy C. Chesterman
DMDomenico Maione
Domenico Maione
Neisseria meningitidis serogroup B (MenB) is the leading cause of meningococcal meningitis and sepsis in industrialized countries, with the highest incidence in infants and adolescents. Two recombinant protein vaccines that protect against MenB are now available (i.e. 4CMenB and MenB-fHbp). Both vaccines contain the Factor H Binding Protein (fHbp) antigen, which can bind the Human Factor H (fH), the main negative regulator of the alternative complement pathway, thus enabling bacterial survival in the blood. fHbp is present in meningococcal strains as three main variants which are immunologically distinct. Here we sought to obtain detailed information about the epitopes targeted by anti-fHbp antibodies induced by immunization with the 4CMenB multicomponent vaccine. Thirteen anti-fHbp human monoclonal antibodies (mAbs) were identified in a library of over 100 antibody fragments (Fabs) obtained from three healthy adult volunteers immunized with 4CMenB. Herein, the key cross-reactive mAbs were further characterized for antigen binding affinity, complement-mediated serum bactericidal activity (SBA) and the ability to inhibit binding of fH to live bacteria. For the first time, we identified a subset of anti-fHbp mAbs able to elicit human SBA against strains with all three variants and able to compete with human fH for fHbp binding. We present the crystal structure of fHbp v1.1 complexed with human antibody 4B3. The structure, combined with mutagenesis and binding studies, revealed the critical cross-reactive epitope. The structure also provided the molecular basis of competition for fH binding. These data suggest that the fH binding site on fHbp v1.1 can be accessible to the human immune system upon immunization, enabling elicitation of human mAbs broadly protective against MenB. The novel structural, biochemical and functional data are of great significance because the human vaccine-elicited mAbs are the first reported to inhibit the binding of fH to fHbp, and are bactericidal with human complement. Our studies provide molecular insights into the human immune response to the 4CMenB meningococcal vaccine and fuel the rationale for combined structural, immunological and functional studies when seeking deeper understanding of the mechanisms of action of human vaccines. Serogroup B meningococcus is a human pathogen causing meningitis and sepsis, especially in infants and adolescents. The recent development of two vaccines (4CMenB, MenB-fHbp) provides an opportunity to reduce disease incidence. One vaccine component is the factor H binding protein (fHbp), which exists in three main variants. On the meningococcal surface, fHbp recruits the human complement-downregulating factor H (fH), allowing the bacterium to evade the host immune system. Analyses of antibodies from vaccinated humans can yield insights into vaccine mechanisms of action. Recently, analyses of the response to 4CMenB vaccination identified thirteen new antibodies able to bind all three fHbp variants. We characterized all 13 antibodies. One of them, 4B3, is the first human antibody reported to effectively mediate bactericidal killing of meningococcal strains expressing each of the three fHbp variants and to compete with human fH for binding to fHbp. We present the three-dimensional structure of 4B3 complexed with fHbp, molecular details that explain how 4B3 can cross-react with all different fHbp variants and why it is so potent. This study provides a deeper understanding of 4CMenB vaccine-induced antibodies, and guidance for the rational design of antigens inducing broadly protective immunity.

5 October 2019 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
FBFederica Bianchi
Federica Bianchi
DVDaniele Veggi
Daniele Veggi
LSLaura Santini
Laura Santini
FBFrancesca Buricchi
Francesca Buricchi
EBErika Bartolini
Erika Bartolini
RCRoberta Cozzi
Roberta Cozzi
The 4 component meningococcus B vaccine (4CMenB) vaccine is the first vaccine containing recombinant proteins licensed for the prevention of invasive meningococcal disease caused by meningococcal serogroup B strains. 4CMenB contains 3 main recombinant proteins, including the Neisseria meningitidis factor H binding protein (fHbp), a lipoprotein able to bind the human factor H. To date, over 1000 aa sequences of fHbp have been identified, and they can be divided into variant groups 1, 2, and 3, which are usually not crossprotective. Nevertheless, previous characterizations of a small set ( n = 10) of mAbs generated in humans after 4CMenB immunization revealed 2 human Fabs (huFabs) (1A12, 1G3) with some crossreactivity for variants 1, 2, and 3. This unexpected result prompted us to examine a much larger set of human mAbs ( n = 110), with the aim of better understanding the extent and nature of crossreactive anti‐fHbp antibodies. In this study, we report an analysis of the human antibody response to fHbp, by the characterization of 110 huFabs collected from 3 adult vaccinees during a 6‐mo study. Although the 4CMenB vaccine contains fHbp variant 1, 13 huFabs were also found to be crossreactive with variants 2 and 3. The crystal structure of the crossreactive huFab 1E6 in complex with fHbp variant 3 was determined, revealing a novel, highly conserved epitope distinct from the epitopes recognized by 1A12 or 1G3. Further, functional characterization shows that human mAb 1E6 is able to elicit rabbit, but not human, complement‐mediated bactericidal activity against meningococci displaying fHbp from any of the 3 different variant groups. This functional and structural information about the human antibody response upon 4CMenB immunization contributes to further unraveling the immunogenic properties of fHbp. Knowledge gained about the epitope profile recognized by the human antibody repertoire could guide future vaccine design.—Bianchi, F., Veggi, D., Santini, L., Buricchi, F., Bartolini, E., Lo Surdo, P., Martinelli, M., Finco, O., Masignani, V., Bottomley, M. J., Maione, D., Cozzi, R. Cocrystal structure of meningococcal factor H binding protein variant 3 reveals a new crossprotective epitope recognized by human mAb 1E6. FASEB J. 33, 12099‐12111 (2019). www.fasebj.org

17 February 2022 in iScience
Verified
Journal Article
Open access
SNSonia Nicchi
Sonia Nicchi
FGFabiola Giusti
Fabiola Giusti
SCStefano Carello
Stefano Carello
SLSabrina Utrio Lanfaloni
Sabrina Utrio Lanfaloni
STSimona Tavarini
Simona Tavarini
CBCecilia Brettoni
Cecilia Brettoni
Moraxella catarrhalis and nontypeable Haemophilus influenzae (NTHi) are pathogenic bacteria frequently associated with exacerbation of chronic obstructive pulmonary disease (COPD), whose hallmark is inflammatory oxidative stress. Neutrophils produce reactive oxygen species (ROS) which can boost antimicrobial response by promoting neutrophil extracellular traps (NET) and autophagy. Here, we showed that M. catarrhalis induces less ROS and NET production in differentiated HL-60 cells compared to NTHi. It is also able to actively interfere with these responses in chemically activated cells in a phagocytosis and opsonin-independent and contact-dependent manner, possibly by engaging host immunosuppressive receptors. M. catarrhalis subverts the autophagic pathway of the phagocytic cells and survives intracellularly. It also promotes the survival of NTHi which is otherwise susceptible to the host antimicrobial arsenal. In-depth understanding of the immune evasion strategies exploited by these two human pathogens could suggest medical interventions to tackle COPD and potentially other diseases in which they co-exist.